Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression

  • Rea, Anna|||0000-0003-1307-8045
  • Santana-Hernández, Sara|||0000-0001-7440-8445
  • Villanueva, Javier
  • Sanvicente-García, Marta|||0000-0002-4508-2834
  • Cabo, Mariona
  • Suarez-Olmos, Jesús
  • Quimis, Fabricio
  • Qin, Mengjuan|||0000-0001-7014-7188
  • Llorens, Eduard
  • Blasco-Benito, Sandra
  • Torralba-Raga, Lamberto
  • Perez, Lorena
  • Bhattarai, Bishan
  • Alari Pahissa, Elisenda|||0000-0001-7424-5383
  • Georgoudaki, Anna-Maria
  • Balaguer, Francesc|||0000-0002-0206-0539
  • Juan, Manel|||0000-0002-3064-1648
  • Pardo, Julián|||0000-0003-0154-0730
  • Celià-Terrassa, Toni|||0000-0002-0615-8744
  • Rovira, Ana|||0000-0003-1301-2599
  • Möker, Nina
  • Zhang, Congcong|||0000-0003-3693-4705
  • Colonna, Marco|||0000-0001-5222-4987
  • Spanholtz, Jan|||0000-0001-7152-6956
  • Malmberg, Karl-Johan|||0000-0002-8718-9373
  • Montagut, Clara
  • Albanell Mestres, Joan|||0000-0003-1239-4580
  • Güell, Marc|||0000-0003-4000-7912
  • López-Botet, Miguel|||0000-0003-4882-065X
  • Muntasell i Castellví, Aura|||0000-0003-2894-0486
Transforming growth factor beta (TGFβ) and activin A suppress natural killer (NK) cell function and proliferation, limiting the efficacy of adoptive NK cell therapies. Inspired by the partial resistance to TGFβ of NK cells with SMAD4 haploinsufficiency, we used CRISPR-Cas9 for knockout of SMAD4 in human NK cells. Here we show that SMAD4 NK cells were resistant to TGFβ and activin A inhibition, retaining their cytotoxicity, cytokine secretion and interleukin-2/interleukin-15-driven proliferation. They showed enhanced tumor penetration and tumor growth control, both as monotherapy and in combination with tumor-targeted therapeutic antibodies. Notably, SMAD4 NK cells outperformed control NK cells treated with a TGFβ inhibitor, underscoring the benefit of maintaining SMAD4-independent TGFβ signaling. SMAD4 conferred TGFβ resistance across diverse NK cell platforms, including CD19-CAR NK cells, stem cell-derived NK cells and ADAPT-NK cells. These findings position SMAD4 knockout as a versatile and compelling strategy to enhance NK cell antitumor activity, providing a new avenue for improving NK cell-based cancer immunotherapies.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Epitope characterization of a monoclonal antibody that selectively recognizes KIR2DL1 allotypes

  • Falco, Michela
  • Meazza, Raffaella
  • Alicata, Claudia
  • Canevali, Paolo
  • Muntasell i Castellví, Aura, 1972-
  • Bottino, Cristina
  • Moretta, Lorenzo
  • Pende, Daniela
  • López-Botet, M. (Miguel)
Killer immunoglobulin-like receptor (KIR) genes code for a family of inhibitory and activating receptors, finely tuning NK cell function. Numerous studies reported the relevance of KIR allelic polymorphism on KIR expression, ligand affinity, and strength in signal transduction. Although KIR variability, including gene copy number and allelic polymorphism, in combination with HLA class I polymorphism, impacts both KIR expression and NK cell education, only a precise phenotypic analysis can define the size of the different KIRpos NK cell subsets. In this context, reagents recognizing a limited number of KIRs is essential. In this study, we have characterized the specificity of an anti-KIR mAb termed HP-DM1. Testing its binding to HEK-293T cells transfected with plasmids coding for different KIRs, we demonstrated that HP-DM1 mAb exclusively reacts with KIR2DL1. Using site-directed mutagenesis, we identified the four amino acids relevant for HP-DM1 recognition: M44, S67, R68, and T70. HP-DM1 mAb binds to a conformational epitope including M44, the residue crucial for HLA-C K80 recognition by KIR2DL1. Based on the HP-DM1 epitope characterization, we could extend its reactivity to all KIR2DL1 allotypes identified except for KIR2DL1*022 and, most likely, KIR2DL1*020, predicting that it does not recognize any other KIR with the only exception of KIR2DS1*013. Moreover, by identifying the residues relevant for HP-DM1 binding, continuously updating of its reactivity will be facilitated., This work was supported by Italian Ministry of Health (Ricerca Corrente G. Gaslini, Ricerca Corrente Ospedale Policlinico San Martino) (Cristina Bottino and Daniela Pende), Instituto de Salud Carlos III, FIS00/0181 (to Miguel Lopez-Botet), H2020-MSCA-ITN-2017-765104-MATURE-NK (to Miguel Lopez-Botet and Daniela Pende), AIRC 5×1000 2018 id. 21147 (Lorenzo Moretta).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression

  • Rea, Anna
  • Santana-Hernández, Sara
  • Villanueva, Javier
  • Sanvicente-García, Marta
  • Cabo, Mariona, 1991-
  • Suárez Olmos, Jesús
  • Quimis, Fabricio
  • Qin, Mengjuan
  • Llorens, Eduard
  • Blasco-Benito, Sandra
  • Alari-Pahissa, Elisenda
  • Celià-Terrassa, Toni
  • Montagut Viladot, Clara
  • Albanell Mestres, Joan
  • Güell Cargol, Marc, 1982-
  • López-Botet, M. (Miguel)
  • Muntasell i Castellví, Aura, 1972-
Transforming growth factor beta (TGFβ) and activin A suppress natural killer (NK) cell function and proliferation, limiting the efficacy of adoptive NK cell therapies. Inspired by the partial resistance to TGFβ of NK cells with SMAD4 haploinsufficiency, we used CRISPR-Cas9 for knockout of SMAD4 in human NK cells. Here we show that SMAD4KO NK cells were resistant to TGFβ and activin A inhibition, retaining their cytotoxicity, cytokine secretion and interleukin-2/interleukin-15-driven proliferation. They showed enhanced tumor penetration and tumor growth control, both as monotherapy and in combination with tumor-targeted therapeutic antibodies. Notably, SMAD4KO NK cells outperformed control NK cells treated with a TGFβ inhibitor, underscoring the benefit of maintaining SMAD4-independent TGFβ signaling. SMAD4KO conferred TGFβ resistance across diverse NK cell platforms, including CD19-CAR NK cells, stem cell-derived NK cells and ADAPT-NK cells. These findings position SMAD4 knockout as a versatile and compelling strategy to enhance NK cell antitumor activity, providing a new avenue for improving NK cell-based cancer immunotherapies., This work was supported by grants PI19/00328 and PI22/00040 (to A.M.), ICI24/00041 (to A.M. and C.M.), PI21/00002 (to J.A.) funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, Generalitat de Catalunya SGR863 (to M.L.-B. and A.M.), 2024PROD00086 (to A.M.), EC Horizon 2020 Marie Sklodowska Curie-Innovative Training Network 765104 (to A. Rea, M.L.-B., N.M., K.-J.M. and J.S.), Ministerio de Ciencia, Innovación y Universidades/FEDER CNS2023-144487 (to A.M.), CIBERONC: CB16/12/00241 (to J.A.), PID2020-113963RBI00 (to J.P.), PID2023-147310OB-I00 (to T.C.-T.), Gobierno de Aragón B29-23R (to J.P.), AECC postdoctoral fellowship POSTD234709BLAS (to S.B.-B.), Research Council of Norway 275469 and 237579 (to K.-J.M.), the Research Council of Norway through its Centres of Excellence scheme 332727 (to K.-J.M.), the Norwegian Cancer Society-190386, 223310 (to K.-J.M.), The South-Eastern Norway Regional Health Authority 2021-073 and 2024-053 (to K.-J.M.), Knut and Alice Wallenberg Foundation 2018.0106 (to K.-J.M.), Swedish Foundation for Strategic Research (to K.-J.M.) and the US National Cancer Institute P01 CA111412, P009500901 (to K.-J.M.) and CRIS EXCELLENCE 19–30, funded by CRIS Contra el Cáncer (to C.M.).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer

  • Santana-Hernández, Sara
  • Suárez Olmos, Jesús
  • Servitja Tormo, Sonia
  • Berenguer-Molins, Pau
  • Costa García, Marcel, 1989-
  • Comerma Blesa, Laura, 1983-
  • Rea, Anna
  • Perera Bel, Júlia
  • Menendez Romero, Silvia
  • Arpí Llucià, Oriol
  • Bermejo, Begoña
  • Martínez, María Teresa
  • Cejalvo, Juan Miguel
  • Comino-Méndez, Iñaki
  • Pascual, Javier
  • Alba, Emilio
  • López-Botet, M. (Miguel)
  • Rojo, Federico
  • Rovira, Ana
  • Albanell Mestres, Joan
  • Muntasell i Castellví, Aura, 1972-
Background: The variability in responses to neoadjuvant treatment with anti-HER2 antibodies prompts to personalized clinical management and the development of innovative treatment strategies. Tumor-infiltrating Natural Killer (TI-NK) cells can predict the efficacy of HER2-targeted antibodies independently from clinicopathological factors in primary HER2-positive breast cancer patients. Understanding the mechanism/s underlying this association would contribute to optimizing patient stratification and provide the rationale for combinatorial approaches with immunotherapy. Methods: We sought to uncover processes enriched in NK cell-infiltrated tumors as compared to NK cell-desert tumors by microarray analysis. Findings were validated in clinical trial-derived transcriptomic data. In vitro and in vivo preclinical models were used for mechanistic studies. Findings were analysed in clinical samples (tumor and serum) from breast cancer patients. Results: NK cell-infiltrated tumors were enriched in CCL5/IFNG-CXCL9/10 transcripts. In multivariate logistic regression analysis, IFNG levels underlie the association between TI-NK cells and pathological complete response to neoadjuvant treatment with trastuzumab. Mechanistically, the production of IFN-ɣ by CD16+ NK cells triggered the secretion of CXCL9/10 from cancer cells. This effect was associated to tumor growth control and the conversion of CD16 into CD16-CD103+ NK cells in humanized in vivo models. In human breast tumors, the CD16 and CD103 markers identified lineage-related NK cell subpopulations capable of producing CCL5 and IFN-ɣ, which correlated with tissue-resident CD8+ T cells. Finally, an early increase in serum CCL5/CXCL9 levels identified patients with NK cell-rich tumors showing good responses to anti-HER2 antibody-based neoadjuvant treatment. Conclusions: This study identifies specialized NK cell subsets as the source of IFN-ɣ influencing the clinical efficacy of anti-HER2 antibodies. It also reveals the potential of serum CCL5/CXCL9 as biomarkers for identifying patients with NK cell-rich tumors and favorable responses to anti-HER2 antibody-based neoadjuvant treatment., AM is supported by ISCiii/FEDER (PI19/00328, PI22/00040 and CIBERONC). The authors are supported by coordinated research projects from Asociación Española contra el Cáncer (GCB15152947MELE). AM and MLB are supported by Generalitat de Catalunya (2017 SGR 888 and 2023 SGR 863). ARe is funded by EC Horizon 2020. Marie Sklodowska Curie-Innovative Training Network (No. 765104; 2018–2021). JA, FR and AR are supported by ISCiii/FEDER (PI18/00006; PI21/00002 and CIBERONC) and by Generalitat de Catalunya (2017 SGR 507; 2021 SGR00776).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Characterization of KIR + NK cell subsets with a monoclonal antibody selectively recognizing KIR2DL1 and blocking the specific interaction with HLA-C

  • Meazza, Raffaella
  • Falco, Michela
  • Canevali, Paolo
  • Loiacono, Fabrizio
  • Colomar-Carando, Natalia
  • Muntasell i Castellví, Aura, 1972-
  • Rea, Anna
  • Mingari, Maria Cristina
  • Locatelli, Franco
  • Moretta, Lorenzo
  • López-Botet, M. (Miguel)
  • Pende, Daniela
The phenotypic identification of different NK cell subsets allows more in-depth characterization of KIR repertoire and function, which are of potential interest in KIR and disease association studies. KIR genes are highly polymorphic, but a great homology exists among the various sequences and few monoclonal antibodies (mAbs) specifically recognize a single KIR. This is the case of HP-DM1 which was demonstrated by analysis of cell transfectants and epitope mapping to be exclusively KIR2DL1-specific, covering all allotypes identified to date, except for KIR2DL1*022 and *020, and also to react with KIR2DS1*013. Here, we compared in immunofluorescence analyses the staining of HP-DM1 with other available mAbs to precisely identify KIR2DL1+ NK cells in potential donors for αβT/B-depleted haplo-HSCT, with known KIR genotype. HP-DM1 mAb was used in combination with EB6 or 11PB6 (anti-KIR2DL1/S1 and anti-KIR2DL3*005), 143211 (anti-KIR2DL1/S5), and HP-MA4 (anti-KIR2DL1/S1/S3/S5) mAbs, allowing the accurate identification of different KIR+ NK cell subsets. These phenotypic evaluations appeared useful to dissect the expression pattern of various KIR2D in NK cells from KIR2DL3*005+ individuals, particularly if KIR2DS1 is present. HP-DM1 mAb remarkably refined NK cell phenotyping of donors carrying KIR2DS5, either in the centromeric or telomeric region. Functional assays with KIR2DL1+ /S1+ /S5+ NK cells confirmed that only HP-DM1 exclusively reacts with KIR2DL1. Finally, we demonstrated that HP-DM1 mAb blocked KIR2DL1 recognition of C2+ HLA-C. Altogether, the data support that HP-DM1 is a unique reagent valuable for characterizing KIR+ NK cell subsets., This work was supported by a network grant of the European Commission (H2020-MSCA-ITN-765104-MATURE-NK) to Miguel Lopez-Botet and Daniela Pende; Natalia Colomar-Carando and Anna Rea are fellows in the project. This work was also supported by Italian Ministry of Health (Ricerca Corrente G. Gaslini, Ricerca Corrente and 5xmille-2016 Ospedale Policlinico San Martino), Fondazione AIRC 5 per mille 2018 id 21147 to Franco Locatelli and Lorenzo Moretta.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression

  • Rea, Anna
  • Santana-Hernández, Sara
  • Villanueva, Javier
  • Sanvicente-García, Marta
  • Cabo, Mariona, 1991-
  • Suárez Olmos, Jesús
  • Quimis, Fabricio
  • Qin, Mengjuan
  • Llorens, Eduard
  • Blasco-Benito, Sandra
  • Alari-Pahissa, Elisenda
  • Celià-Terrassa, Toni
  • Montagut Viladot, Clara
  • Albanell Mestres, Joan
  • Güell Cargol, Marc, 1982-
  • López-Botet, M. (Miguel)
  • Muntasell i Castellví, Aura, 1972-
Transforming growth factor beta (TGFβ) and activin A suppress natural killer (NK) cell function and proliferation, limiting the efficacy of adoptive NK cell therapies. Inspired by the partial resistance to TGFβ of NK cells with SMAD4 haploinsufficiency, we used CRISPR-Cas9 for knockout of SMAD4 in human NK cells. Here we show that SMAD4KO NK cells were resistant to TGFβ and activin A inhibition, retaining their cytotoxicity, cytokine secretion and interleukin-2/interleukin-15-driven proliferation. They showed enhanced tumor penetration and tumor growth control, both as monotherapy and in combination with tumor-targeted therapeutic antibodies. Notably, SMAD4KO NK cells outperformed control NK cells treated with a TGFβ inhibitor, underscoring the benefit of maintaining SMAD4-independent TGFβ signaling. SMAD4KO conferred TGFβ resistance across diverse NK cell platforms, including CD19-CAR NK cells, stem cell-derived NK cells and ADAPT-NK cells. These findings position SMAD4 knockout as a versatile and compelling strategy to enhance NK cell antitumor activity, providing a new avenue for improving NK cell-based cancer immunotherapies., This work was supported by grants PI19/00328 and PI22/00040 (to A.M.), ICI24/00041 (to A.M. and C.M.), PI21/00002 (to J.A.) funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, Generalitat de Catalunya SGR863 (to M.L.-B. and A.M.), 2024PROD00086 (to A.M.), EC Horizon 2020 Marie Sklodowska Curie-Innovative Training Network 765104 (to A. Rea, M.L.-B., N.M., K.-J.M. and J.S.), Ministerio de Ciencia, Innovación y Universidades/FEDER CNS2023-144487 (to A.M.), CIBERONC: CB16/12/00241 (to J.A.), PID2020-113963RBI00 (to J.P.), PID2023-147310OB-I00 (to T.C.-T.), Gobierno de Aragón B29-23R (to J.P.), AECC postdoctoral fellowship POSTD234709BLAS (to S.B.-B.), Research Council of Norway 275469 and 237579 (to K.-J.M.), the Research Council of Norway through its Centres of Excellence scheme 332727 (to K.-J.M.), the Norwegian Cancer Society-190386, 223310 (to K.-J.M.), The South-Eastern Norway Regional Health Authority 2021-073 and 2024-053 (to K.-J.M.), Knut and Alice Wallenberg Foundation 2018.0106 (to K.-J.M.), Swedish Foundation for Strategic Research (to K.-J.M.) and the US National Cancer Institute P01 CA111412, P009500901 (to K.-J.M.) and CRIS EXCELLENCE 19–30, funded by CRIS Contra el Cáncer (to C.M.).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Characterization of KIR + NK cell subsets with a monoclonal antibody selectively recognizing KIR2DL1 and blocking the specific interaction with HLA-C

  • Meazza, Raffaella
  • Falco, Michela
  • Canevali, Paolo
  • Loiacono, Fabrizio
  • Colomar-Carando, Natalia
  • Muntasell i Castellví, Aura, 1972-
  • Rea, Anna
  • Mingari, Maria Cristina
  • Locatelli, Franco
  • Moretta, Lorenzo
  • López-Botet, M. (Miguel)
  • Pende, Daniela
The phenotypic identification of different NK cell subsets allows more in-depth characterization of KIR repertoire and function, which are of potential interest in KIR and disease association studies. KIR genes are highly polymorphic, but a great homology exists among the various sequences and few monoclonal antibodies (mAbs) specifically recognize a single KIR. This is the case of HP-DM1 which was demonstrated by analysis of cell transfectants and epitope mapping to be exclusively KIR2DL1-specific, covering all allotypes identified to date, except for KIR2DL1*022 and *020, and also to react with KIR2DS1*013. Here, we compared in immunofluorescence analyses the staining of HP-DM1 with other available mAbs to precisely identify KIR2DL1+ NK cells in potential donors for αβT/B-depleted haplo-HSCT, with known KIR genotype. HP-DM1 mAb was used in combination with EB6 or 11PB6 (anti-KIR2DL1/S1 and anti-KIR2DL3*005), 143211 (anti-KIR2DL1/S5), and HP-MA4 (anti-KIR2DL1/S1/S3/S5) mAbs, allowing the accurate identification of different KIR+ NK cell subsets. These phenotypic evaluations appeared useful to dissect the expression pattern of various KIR2D in NK cells from KIR2DL3*005+ individuals, particularly if KIR2DS1 is present. HP-DM1 mAb remarkably refined NK cell phenotyping of donors carrying KIR2DS5, either in the centromeric or telomeric region. Functional assays with KIR2DL1+ /S1+ /S5+ NK cells confirmed that only HP-DM1 exclusively reacts with KIR2DL1. Finally, we demonstrated that HP-DM1 mAb blocked KIR2DL1 recognition of C2+ HLA-C. Altogether, the data support that HP-DM1 is a unique reagent valuable for characterizing KIR+ NK cell subsets., This work was supported by a network grant of the European Commission (H2020-MSCA-ITN-765104-MATURE-NK) to Miguel Lopez-Botet and Daniela Pende; Natalia Colomar-Carando and Anna Rea are fellows in the project. This work was also supported by Italian Ministry of Health (Ricerca Corrente G. Gaslini, Ricerca Corrente and 5xmille-2016 Ospedale Policlinico San Martino), Fondazione AIRC 5 per mille 2018 id 21147 to Franco Locatelli and Lorenzo Moretta.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Epitope characterization of a monoclonal antibody that selectively recognizes KIR2DL1 allotypes

  • Falco, Michela
  • Meazza, Raffaella
  • Alicata, Claudia
  • Canevali, Paolo
  • Muntasell i Castellví, Aura, 1972-
  • Bottino, Cristina
  • Moretta, Lorenzo
  • Pende, Daniela
  • López-Botet, M. (Miguel)
Killer immunoglobulin-like receptor (KIR) genes code for a family of inhibitory and activating receptors, finely tuning NK cell function. Numerous studies reported the relevance of KIR allelic polymorphism on KIR expression, ligand affinity, and strength in signal transduction. Although KIR variability, including gene copy number and allelic polymorphism, in combination with HLA class I polymorphism, impacts both KIR expression and NK cell education, only a precise phenotypic analysis can define the size of the different KIRpos NK cell subsets. In this context, reagents recognizing a limited number of KIRs is essential. In this study, we have characterized the specificity of an anti-KIR mAb termed HP-DM1. Testing its binding to HEK-293T cells transfected with plasmids coding for different KIRs, we demonstrated that HP-DM1 mAb exclusively reacts with KIR2DL1. Using site-directed mutagenesis, we identified the four amino acids relevant for HP-DM1 recognition: M44, S67, R68, and T70. HP-DM1 mAb binds to a conformational epitope including M44, the residue crucial for HLA-C K80 recognition by KIR2DL1. Based on the HP-DM1 epitope characterization, we could extend its reactivity to all KIR2DL1 allotypes identified except for KIR2DL1*022 and, most likely, KIR2DL1*020, predicting that it does not recognize any other KIR with the only exception of KIR2DS1*013. Moreover, by identifying the residues relevant for HP-DM1 binding, continuously updating of its reactivity will be facilitated., This work was supported by Italian Ministry of Health (Ricerca Corrente G. Gaslini, Ricerca Corrente Ospedale Policlinico San Martino) (Cristina Bottino and Daniela Pende), Instituto de Salud Carlos III, FIS00/0181 (to Miguel Lopez-Botet), H2020-MSCA-ITN-2017-765104-MATURE-NK (to Miguel Lopez-Botet and Daniela Pende), AIRC 5×1000 2018 id. 21147 (Lorenzo Moretta).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer

  • Santana-Hernández, Sara
  • Suárez Olmos, Jesús
  • Servitja Tormo, Sonia
  • Berenguer-Molins, Pau
  • Costa García, Marcel, 1989-
  • Comerma Blesa, Laura, 1983-
  • Rea, Anna
  • Perera Bel, Júlia
  • Menendez Romero, Silvia
  • Arpí Llucià, Oriol
  • Bermejo, Begoña
  • Martínez, María Teresa
  • Cejalvo, Juan Miguel
  • Comino-Méndez, Iñaki
  • Pascual, Javier
  • Alba, Emilio
  • López-Botet, M. (Miguel)
  • Rojo, Federico
  • Rovira, Ana
  • Albanell Mestres, Joan
  • Muntasell i Castellví, Aura, 1972-
Background: The variability in responses to neoadjuvant treatment with anti-HER2 antibodies prompts to personalized clinical management and the development of innovative treatment strategies. Tumor-infiltrating Natural Killer (TI-NK) cells can predict the efficacy of HER2-targeted antibodies independently from clinicopathological factors in primary HER2-positive breast cancer patients. Understanding the mechanism/s underlying this association would contribute to optimizing patient stratification and provide the rationale for combinatorial approaches with immunotherapy. Methods: We sought to uncover processes enriched in NK cell-infiltrated tumors as compared to NK cell-desert tumors by microarray analysis. Findings were validated in clinical trial-derived transcriptomic data. In vitro and in vivo preclinical models were used for mechanistic studies. Findings were analysed in clinical samples (tumor and serum) from breast cancer patients. Results: NK cell-infiltrated tumors were enriched in CCL5/IFNG-CXCL9/10 transcripts. In multivariate logistic regression analysis, IFNG levels underlie the association between TI-NK cells and pathological complete response to neoadjuvant treatment with trastuzumab. Mechanistically, the production of IFN-ɣ by CD16+ NK cells triggered the secretion of CXCL9/10 from cancer cells. This effect was associated to tumor growth control and the conversion of CD16 into CD16-CD103+ NK cells in humanized in vivo models. In human breast tumors, the CD16 and CD103 markers identified lineage-related NK cell subpopulations capable of producing CCL5 and IFN-ɣ, which correlated with tissue-resident CD8+ T cells. Finally, an early increase in serum CCL5/CXCL9 levels identified patients with NK cell-rich tumors showing good responses to anti-HER2 antibody-based neoadjuvant treatment. Conclusions: This study identifies specialized NK cell subsets as the source of IFN-ɣ influencing the clinical efficacy of anti-HER2 antibodies. It also reveals the potential of serum CCL5/CXCL9 as biomarkers for identifying patients with NK cell-rich tumors and favorable responses to anti-HER2 antibody-based neoadjuvant treatment., AM is supported by ISCiii/FEDER (PI19/00328, PI22/00040 and CIBERONC). The authors are supported by coordinated research projects from Asociación Española contra el Cáncer (GCB15152947MELE). AM and MLB are supported by Generalitat de Catalunya (2017 SGR 888 and 2023 SGR 863). ARe is funded by EC Horizon 2020. Marie Sklodowska Curie-Innovative Training Network (No. 765104; 2018–2021). JA, FR and AR are supported by ISCiii/FEDER (PI18/00006; PI21/00002 and CIBERONC) and by Generalitat de Catalunya (2017 SGR 507; 2021 SGR00776).